Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. - Wikidata - thesis-toulmin - TriplyDB

Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus.

Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus.

http://www.wikidata.org/entity/Q35555433

about

Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus Immunomodulatory interventions for focal epilepsy syndromes Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus Current and emerging treatment options in the management of lupus Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives Non-invasive imaging to monitor lupus nephritis and neuropsychiatric systemic lupus erythematosus Neuropsychiatric lupus: a mosaic of clinical presentations Clinical features and outcome of neuropsychiatric lupus in Chinese: analysis of 240 hospitalized patients.Cerebellar ataxia in systemic lupus erythematosus.A case of spontaneous hemoperitoneum presenting as the initial manifestation of systemic lupus erythematosus Association between low-dose pulsed intravenous cyclophosphamide therapy and amenorrhea in patients with systemic lupus erythematosus: a case-control study.A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis.Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus Neurologic manifestations of systemic lupus erythematosus in children and adults.Neuropsychiatric Symptoms in Lupus Recurrent lower motor neuron type facial palsy: an unusual manifestation of SLE Neuropsychiatric systemic lupus erythematosus: a diagnostic challenge Pulse cyclophosphamide therapy in the management of patients with macular serpiginous choroidopathy.Immune mediated diseases and immune modulation in the neurocritical care unit Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus Peripheral neuropathies due to systemic lupus erythematosus in China.Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study.Metabolism and transport of oxazaphosphorines and the clinical implications.Contemporary treatment of systemic lupus erythematosus: an update for clinicians.Treatment of acute relapses in multiple sclerosis.Emerging drug therapies for systemic lupus erythematosus.Juvenile systemic lupus erythematosus with primary neuropsychiatric presentation.High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus.Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future--the EULAR recommendations for the management of SLE and the use of end-points in clinical trials.SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus.Chemosis as a presenting symptom of systemic lupus erythematosus.Myelitis in systemic lupus erythematosus: clinical features, immunological profile and magnetic resonance imaging of five cases.Is it relevant to screen young women hospitalized in psychiatric department for neuropsychiatric systemic lupus erythematosus (NPSLE)?: A prospective study of 100 psychiatric inpatients Update on emerging drug therapies for systemic lupus erythematosus.Neuropsychiatric lupus: clinical challenges, brain-reactive autoantibodies and treatment strategies.Optic neuropathy as a presenting feature of systemic lupus erythematosus: two case reports and literature review.Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management.Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report.Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus.

P2860

Q24200954-CB346843-0853-436E-B320-6BDBD7892AFC Q24201788-5330AA04-67FB-464E-8674-A99D400856E5 Q24246092-6CAAA1C4-0677-4F0E-8EEB-2C49A38807AC Q26741266-A4F22D3C-0BD1-41A4-8B5A-12929FD03CE3 Q26774815-279A3271-DD5D-46D6-859F-85DA92D43076 Q26796871-CC6F1EB9-0E15-4272-9BDF-8642D5EF2525 Q27027588-AEDD4106-AC3C-4C95-BE5F-B5E776915EF6 Q31145482-C16A3A20-4E11-4BA4-88AB-4DAFDA966FEB Q33386680-FDC32F50-9FDD-4403-B2C5-39AF2ED85ABF Q33393399-42E6F587-0828-479B-9585-3E753A06D293 Q33929673-D7353C00-55F9-4661-A595-2073B1686448 Q34024209-D99DB5E0-5A45-41D5-B9E4-A039B99DE5E5 Q34087831-05B98A6E-02E3-4FFC-9F9B-7A3008F473DC Q34310715-4053D5AD-1061-49B5-8F9A-6B7E20754D47 Q34459628-0629CE4F-8FA7-4ADC-A603-2E3D3AD2AFD8 Q34707551-BC393FD3-2428-4AA4-A8B2-E7FB2DC07B13 Q35204117-C61A4380-A1C9-4212-9064-A29F239F30F7 Q35722478-6407D65F-C9C3-40AD-8DCB-18E586AF5F75 Q35729575-A4C4464C-DD2C-4953-9348-BCCFF10D2336 Q35760171-2229EC3C-E15A-4CB0-AD18-1C3ACD53A8CD Q35827846-DDF5A209-A6C4-4083-B53E-D34553BA8B82 Q36151124-A46015EA-A667-40B4-8D13-061A963FA50F Q36307414-2F8D2C34-2039-4B72-ADCD-D6792D82AC79 Q36360811-92782494-6FCF-4D78-B1B9-F21CC0CD2F01 Q36443689-06D5C43F-7415-4068-9447-B95E907F6B05 Q36568671-9A1B0909-9514-43C2-B278-F23F1E2A726B Q36634248-B25DE216-79F8-4BCC-8874-F66E174072AE Q36702788-7EF01CD3-050F-477F-8346-76990BD7F669 Q36896784-1CB1CE62-AA82-4997-9CD4-E758C9E08035 Q37168033-646874BF-7F93-4DEC-9C69-50C353819D5D Q37226689-4321D5F2-4090-4E64-930A-3A460EE410EE Q37414041-ACB0F475-1902-45B6-BABF-7B261A95184B Q37456167-C1BD4B1D-7359-4DAD-B462-CADAFBFA6A48 Q37468127-1B56744F-6399-4E0C-96BA-84BE4D60BAA9 Q37690745-5FF3459F-DFCD-47C3-9901-00E27577D5B5 Q37800296-CFD9B040-AC92-4D25-983C-7036F857CEBB Q37888952-0C15FB18-4A32-41EF-80FF-06BC7A94FB00 Q37922765-4EACD8AB-39F8-4810-917C-4611E54BD6FD Q37954539-DE94438A-78EC-4498-8165-19CEC161CEB6 Q37960525-25354ABD-20A8-4F7D-8450-A4FC8D181B31

P2860

Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus.

http://www.wikidata.org/entity/Q35555433

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Controlled clinical trial of I ...... systemic lupus erythematosus.

@ast

Controlled clinical trial of I ...... systemic lupus erythematosus.

@en

type

label

Controlled clinical trial of I ...... systemic lupus erythematosus.

@ast

Controlled clinical trial of I ...... systemic lupus erythematosus.

@en

prefLabel

Controlled clinical trial of I ...... systemic lupus erythematosus.

@ast

Controlled clinical trial of I ...... systemic lupus erythematosus.

@en

P1433

Q35555433-BDF23275-C6C2-40B8-B56D-E7F559097CFE

P1476

Q35555433-5F5DD76F-03A2-4C55-93CD-FF26E5D9ADBA

P2093

Q35555433-082B56CD-D299-45D1-ACA6-EF58217A3F45

Q35555433-1A9C2938-72F9-446F-93DA-826DED3F7A48

Q35555433-3679E026-9E50-453B-AB7D-BCE25E6399E6

Q35555433-42449C2B-CF4B-4131-97F0-81FDE820A2C6

Q35555433-4F8247E8-C2CD-47AA-AE0F-5715FFF7B27B

Q35555433-728C4C76-9546-43C3-812E-079B9938E5DB

Q35555433-83853E2C-1025-41F9-AFCC-BD6BEBBAD80C

Q35555433-95F826D3-D6A7-4918-A34F-E68E42E44750

Q35555433-A6FB990F-B86B-4320-9830-3B8326B6C6EE

Q35555433-AB77C085-8506-4697-8110-9B2CC9871328

P2860

Q35555433-1236F87A-100E-4732-9C54-8F961050DB85

Q35555433-2E7E6B27-4FAF-4DD8-8018-AF000B7E4986

Q35555433-3565BC2A-57ED-4CA7-A988-FE95A62C52BB

Q35555433-36798FCF-5126-4E7A-9E34-18D5E7BFF337

Q35555433-4571623B-50F6-4C3F-BECB-4E0FFF13344D

Q35555433-464A409D-2133-47D1-B6A3-FE14384347DD

Q35555433-4F113B3C-DED5-403A-9CBA-D31AB5BD7DB8

Q35555433-68D34940-ADE2-4291-9351-21AA36CA6392

Q35555433-777D1BD4-701D-43D4-B66C-BC88859B2598

Q35555433-85EF7EF3-CEEC-4E0D-A136-F5C85F432831

P304

Q35555433-53398C74-4667-4C51-B153-9B4AEF030860

P31

Q35555433-AB2B334C-C5CA-4024-A0D2-A2B339FDBD5B

P356

Q35555433-4DF20FA1-626C-4191-AF34-9385746404C5

P407

Q35555433-4CCF4AC2-CD1E-4BE1-B951-EFA5EE646EFF

P433

Q35555433-79739994-C2B7-4EC7-BE33-0D9E1679FD1D

P478

Q35555433-2419CBBA-E94A-4DFE-B63D-48388CFCA8A5

P577

Q35555433-4F6ADA81-439B-44B3-81FE-37CF3A2B6738

P5875

Q35555433-C238EC9A-CF41-46E7-A6EB-848139C731B6

P698

Q35555433-55711C74-0456-4E4E-903A-FF23FB6F9B56

P932

Q35555433-0E6D47A4-AB90-4DF3-8955-011F41B3271E

P356

ARD.2004.025528

P1433

Annals of the Rheumatic Diseases

P1476

Controlled clinical trial of I ...... systemic lupus erythematosus.

@en

P2093

Alocer-Varela J

http://www.w3.org/2001/XMLSchema#string

Ariza-Andraca R

http://www.w3.org/2001/XMLSchema#string

Barile-Fabris L

http://www.w3.org/2001/XMLSchema#string

Clark P

http://www.w3.org/2001/XMLSchema#string

Fraga-Mouret A

http://www.w3.org/2001/XMLSchema#string

Fuentes de la Mata J

http://www.w3.org/2001/XMLSchema#string

Jara LJ

http://www.w3.org/2001/XMLSchema#string

Miranda-Limón JM

http://www.w3.org/2001/XMLSchema#string

Olguín-Ortega L

http://www.w3.org/2001/XMLSchema#string

Vargas F

http://www.w3.org/2001/XMLSchema#string

P2860

The 1982 revised criteria for the classification of systemic lupus erythematosus

APS and the brain.

Anti beta2-glycoprotein I antibodies: clinical significance.

A conceptual framework for clinical trials in SLE and other multisystem diseases.

Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus.

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis.

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.

The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation.

Endothelium and the brain in CNS lupus.

Central nervous system lupus: a clinical approach to therapy.

P304

620-625

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2004.025528

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7964778

http://www.w3.org/2001/XMLSchema#string

P698

15769918

http://www.w3.org/2001/XMLSchema#string

P932

1755456

http://www.w3.org/2001/XMLSchema#string